A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
This study will evaluate thrice weekly dosing with vintafolide to find the maximum tolerable dose. The primary study hypothesis is that administration of vintafolide to participants with advanced solid tumors will have acceptable safety and tolerability.
Solid Tumor
DRUG: Vintafolide
Number of Participants Experiencing Dose-limiting Toxicities, Up to 28 days
Maximum Plasma Concentration (Cmax) of Vintafolide, Cycle 1, Day1 predose and at 2, 5, 10, 20, 30, 45, 60, 90 and 120 minutes post-dose|Area Under the Plasma Concentration-time Curve (AUC) for Vintafolide, Cycle 1, Day1 predose and at 2, 5, 10, 20, 30, 45, 60, 90 and 120 minutes post-dose|Plasma Concentration of desacetylvinblastine hydrazide (DAVLBH), Cycle 1, Day1 predose and at 2, 5, 10, 20, 30, 45, 60, 90 and 120 minutes post-dose
This study will evaluate thrice weekly dosing with vintafolide to find the maximum tolerable dose. The primary study hypothesis is that administration of vintafolide to participants with advanced solid tumors will have acceptable safety and tolerability.